January 10, 2022 -- Illumina has entered into a definitive co-development agreement with SomaLogic to bring the SomaScan proteomics assay to Illumina's current and future high-throughput next-generation sequencing (NGS) platforms.
By combining Somascan's high-plexity technology with Illumina's existing and future high-throughput NGS platforms, researchers can analyze thousands of samples for more than 10,000 protein targets, the company said.
Illumina will begin a multiyear development effort to integrate SomaLogic's protein target volume with Illumina's sequencing technologies, informatics toolsets, and Dragen software to create a full end-to-end NGS workflow solution.
llumina will further support expansion in proteomics by harnessing the scalability of its NGS platforms and its broad installed base across academic research institutions, medical centers, and biopharma companies while SomaLogic focuses on expansion and innovation of its market-leading protein panel.
No financial details of the partnership were disclosed.